Effect of raloxifene and its interaction with human PTH on bone formation

Abstract We studied the of effects raloxifene alone or in combination with human PTH (hPTH) 1–34 in mineralizing cultures of SaOS-2 cells. Raloxifene ($ 10^{−8} $–$ 10^{−6} $ M) increased bone nodule formation in cultures of SaOS-2 cells when added intermittently from day 8 to day 17. A single 24-h...
Ausführliche Beschreibung

Abstract We studied the of effects raloxifene alone or in combination with human PTH (hPTH) 1–34 in mineralizing cultures of SaOS-2 cells. Raloxifene ($ 10^{−8} $–$ 10^{−6} $ M) increased bone nodule formation in cultures of SaOS-2 cells when added intermittently from day 8 to day 17. A single 24-h treatment with $ 10^{−8} $ M hPTH (1–34) at day 8 reduced the nodule area by 75.6% at day 17, and raloxifene added concomi-tantly with hPTH (1–34) reduced this inhibitory effect in a dose-dependent manner. Raloxifene also reduced the hPTH (1–34)-induced inhibition of alkaline phosphatase (ALP) activity. The 10-fold stimulation of c-fos mRNA expression by hPTH (1–34) was not influenced by raloxifene co-treatment. The protein kinase A (PKA) inhibitor 6–22 amide (1.7 nM) and the protein kinase C (PKC) inhibitor-bisindolylmaleimide 1 (10 nM) did not influence the separate effects of PTH and raloxifene on mineralized bone nodule formation. This is the first report on the interaction of PTH and raloxifene in an osteoblast culture system. Ausführliche Beschreibung